



## Biogen to Present at the Bernstein 34th Annual Strategic Decisions Conference

May 22, 2018

Cambridge, MA, -- [Biogen Inc.](http://www.biogen.com) (NASDAQ: BIIB) announced today that it will present at the Bernstein 34th Annual Strategic Decisions Conference. The webcast will be live on Wednesday, May 30, 2018 at 9:00 a.m. ET. To access the live webcast, please visit Biogen's Investors section at [www.biogen.com/investors](http://www.biogen.com/investors). An archived version of the webcast will be available following the presentation.

### About Biogen

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world's first global biotechnology companies by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer's disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. We routinely post information that may be important to investors on our website at [www.biogen.com](http://www.biogen.com). To learn more, please visit [www.biogen.com](http://www.biogen.com) and follow us on social media – [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#).

### Contact:

Karen Jewell  
Investor Relations  
Biogen  
781.464.2442